revdofilimab (ABBV-368) / AbbVie  >>  Phase 1
Welcome,         Profile    Billing    Logout  

4 Trials

Remove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
revdofilimab (ABBV-368) / AbbVie
NCT03818542: A Study to Assess the Effects of Multiple Study Drug Regimens in Subjects With Newly Diagnosed Locally Advanced Head and Neck Squamous Cell Carcinoma

Terminated
1b
3
US
ABBV-181, ABBV-368, ABBV-927
AbbVie
Head and Neck Cancer
09/20
09/20
NCT04196283: A Study to Determine the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of ABBV-368 Plus Tilsotolimod and Other Therapy Combinations in Participants With Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma

Hourglass Jan 2021 - Dec 2021 : Proof-of-concept data from trial in combination with tilsotolimod for recurrent/metastatic HNSCC
Completed
1b
30
Europe, US, RoW
ABBV-368, Tilsotolimod, Nab-paclitaxel, ABBV-181, Budigalimab
AbbVie, Idera Pharmaceuticals, Inc.
Advanced Solid Tumors Cancer
10/22
10/22
NCT03071757: A Study of the Safety, Tolerability and Pharmacokinetics of ABBV-368 as a Single Agent and Combination in Subjects With Locally Advanced or Metastatic Solid Tumors

Completed
1
139
Europe, Japan, US, RoW
ABBV-368, ABBV-181
AbbVie
Advanced Solid Tumors Cancer
04/22
04/22
NCT03893955: A Study to Determine the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of ABBV-927 With ABBV-368, Budigalimab (ABBV-181) and/or Chemotherapy in Participants With Locally Advanced or Metastatic Solid Tumors

Active, not recruiting
1
150
Europe, US, RoW
ABBV-927, ABBV-368, ABBV-181, Budigalimab, Carboplatin, Nab-paclitaxel
AbbVie
Cancer, Advanced Solid Tumors, Triple-Negative Breast Cancer (TNBC), Non-small-cell-lung-cancer (NSCLC), Metastatic Solid Tumors
09/24
09/24

Download Options